Clinical Trial Detail

NCT ID NCT03700294
Title Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors ADC Therapeutics S.A.
Indications

sarcoma

nasopharynx carcinoma

malignant mesothelioma

colorectal cancer

ovarian cancer

lung non-small cell carcinoma

stomach cancer

head and neck squamous cell carcinoma

pancreatic cancer

esophageal cancer

triple-receptor negative breast cancer

Therapies

ADCT-601

Age Groups: adult senior

No variant requirements are available.